1.Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
2.Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199–1207.
3.Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID–19)-An emerging global health threat. J Infect Public Health. 2020;13(4):644–646.
4.Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID–19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306.
5.Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV–2). Clin Infect Dis. 2020.
6.Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020;46(2):315–328.
7.Klopfenstein T, Kadiane-Oussou NJ, Royer PY, Toko L, Gendrin V, Zayet S. Diarrhea: An underestimated symptom in Coronavirus disease 2019. Clin Res Hepatol Gastroenterol. 2020.
8.Chen T, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID–19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci. 2020.
9.Hjelmesaeth J, Skaare D. Loss of smell or taste as the only symptom of COVID–19. Tidsskr Nor Laegeforen. 2020;140(7).
10.Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
11.Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV–2 in Singapore. JAMA. 2020.
12.Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
13.Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID–19 patients at time of hospital discharge. Eur Respir J. 2020.
14.Hull JH, Lloyd JK, Cooper BG. Lung function testing in the COVID–19 endemic. Lancet Respir Med. 2020.
15.Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID–19: a call to arms? Lancet Respir Med. 2020.
16.Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147–163.
17.Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest. 2012;122(8):2731–2740.
18.Zemans RL, Colgan SP, Downey GP. Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol. 2009;40(5):519–535.
19.Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210.
20.Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID–19: Immunology and treatment options. Clin Immunol. 2020;215:108448.
21.Wen Wen WS, Hao Tang, Wenqing Le, Xiaopeng Zhang, Yingfeng Zheng, XiuXing Liu, Lihui Xie, Jianmin Li, Jinguo Ye, Xiuliang Cui, Yushan Miao, Depeng Wang, Jiantao Dong, View ORCID ProfileChuan-Le Xiao, Wei Chen, Hongyang Wang. Immune Cell Profiling of COVID–19 Patients in the Recovery Stage by Single-Cell Sequencing. 2020.
22.Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID–19. Nat Med. 2020.
23.Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
24.Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
25.DePianto DJ, Chandriani S, Abbas AR, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax. 2015;70(1):48–56.
26.McDonough JE, Ahangari F, Li Q, et al. Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight. 2019;4(22).
27.Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
28.Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5(11):e13984.
29.George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID–19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020.
30.Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019;35(14):i436-i445.
31.Yang X, Shi Y, Li M, et al. Identification and validation of an immune cell infiltrating score predicting survival in patients with lung adenocarcinoma. J Transl Med. 2019;17(1):217.
32.Rohr-Udilova N, Klinglmuller F, Schulte-Hermann R, et al. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep. 2018;8(1):6220.
33.Morpheus.
34.Libraty DH, O’Neil KM, Baker LM, Acosta LP, Olveda RM. Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection. Virology. 2007;368(2):317–321.
35.Wang W, Su B, Pang L, et al. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID–19 patients. Cell Mol Immunol. 2020;17(6):650–652.
36.Xue J, Kass DJ, Bon J, et al. Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol. 2013;191(5):2089–2095.
37.Heukels P, van Hulst JAC, van Nimwegen M, et al. Enhanced Bruton’s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):232.
38.Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008;180(6):3655–3659.
39.Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular Helper T Cells. Annu Rev Immunol. 2016;34:335–368.
40.Asai Y, Chiba H, Nishikiori H, et al. Aberrant populations of circulating T follicular helper cells and regulatory B cells underlying idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):244.
41.Sandra C. A. Nielsen FY, Ramona A. Hoh, Katherine J. L. Jackson, Katharina Roeltgen, Ji-Yeun Lee, Arjun Rustagi, Angela J. Rogers, Abigail E. Powell, Peter S. Kim, Taia T. Wang, Benjamin Pinsky, Catherine A. Blish, Scott D. Boyd. B cell clonal expansion and convergent antibody responses to SARS-CoV–2. Infectious Diseases. 2020.
42.Byrne AJ, Maher TM, Lloyd CM. Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease? Trends Mol Med. 2016;22(4):303–316.
43.Teoh AKY, Jo HE, Chambers DC, et al. Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry. Eur Respir J. 2020;55(4).
44.Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38(4):792–804.
45.Guilliams M, De Kleer I, Henri S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med. 2013;210(10):1977–1992.
46.Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016;44(3):450–462.
47.Luca Carsana M, Aurelio Sonzogni M, Ahmed Nasr M, Roberta Simona Rossi M, Alessandro Pellegrinelli M, Pietro Zerbi M. Pulmonary post-mortem findings in a series of COVID–19 cases from northern Italy: a two-centre descriptive study. The Lancet Infectious Diseases. 2020.
48.Cabrera-Benitez NE, Laffey JG, Parotto M, et al. Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome. Anesthesiology. 2014;121(1):189–198.
49.Abed NS, Chace JH, Fleming AL, Cowdery JS. Interferon-gamma regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-mediated inhibition of B cell differentiation. Cell Immunol. 1994;153(2):356–366.
50.Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV–2-Specific Humoral and Cellular Immunity in COVID–19 Convalescent Individuals. Immunity. 2020.
51.Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV–2 in patients with COVID–19. Nat Med. 2020.
52.Schaefer CF, Anthony K, Krupa S, et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 2009;37(Database issue):D674–679.
53.Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol. 2009;21(5):265–272.
54.Lu TT, Cyster JG. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science. 2002;297(5580):409–412.
55.Carrasco YR, Fleire SJ, Cameron T, Dustin ML, Batista FD. LFA–1/ICAM–1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity. 2004;20(5):589–599.
56.Lam JH, Baumgarth N. The Multifaceted B Cell Response to Influenza Virus. J Immunol. 2019;202(2):351–359.
57.Spaargaren M, Beuling EA, Rurup ML, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med. 2003;198(10):1539–1550.
58.Waffarn EE, Baumgarth N. Protective B cell responses to flu—no fluke! J Immunol. 2011;186(7):3823–3829.
59.Waffarn EE, Hastey CJ, Dixit N, et al. Infection-induced type I interferons activate CD11b on B–1 cells for subsequent lymph node accumulation. Nat Commun. 2015;6:8991.
60.Choi YS, Baumgarth N. Dual role for B–1a cells in immunity to influenza virus infection. J Exp Med. 2008;205(13):3053–3064.
61.Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11(11):762–774.
62.Sorman A, Zhang L, Ding Z, Heyman B. How antibodies use complement to regulate antibody responses. Mol Immunol. 2014;61(2):79–88.
63.Wang H, Coligan JE, Morse HC, 3rd. Emerging Functions of Natural IgM and Its Fc Receptor FCMR in Immune Homeostasis. Front Immunol. 2016;7:99.
64.Dubois B, Massacrier C, Vanbervliet B, et al. Critical role of IL–12 in dendritic cell-induced differentiation of naive B lymphocytes. J Immunol. 1998;161(5):2223–2231.
65.Huse K, Wogsland CE, Polikowsky HG, et al. Human Germinal Center B Cells Differ from Naive and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response. Cytometry A. 2019;95(4):442–449.
66.Matthew Woodruff RR, Kevin Cashman, Doan Nguyen, Ariel Ley, Shuya Kyu, Ankur Saini, Natalie Haddad, Weirong Chen, J. Christina Howell, Tugba Ozturk, Saeyun Lee, Jacob Estrada, Andrea Morrison-Porter, Andrew Derrico, Fabliha Anam, Henry Wu, Sang Le, Scott Jenks, Wiliam Hu, F. Eun-Hyung Lee, Ignacio Sanz. Critically ill SARS-CoV–2 patients display lupus-like hallmarks of extrafollicular B cell activation. 2020.
67.Quinti I, Lougaris V, Milito C, et al. A possible role for B cells in COVID–19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020.
68.Agematsu K, Futatani T, Hokibara S, et al. Absence of memory B cells in patients with common variable immunodeficiency. Clin Immunol. 2002;103(1):34–42.
69.Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA). Front Biosci. 2000;5:D917–928.
70.Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 2014;10(6):957–967.
71.Raedler LA. Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenstrom’s Macroglobulinemia. Am Health Drug Benefits. 2016;9(Spec Feature):89–92.
72.Drennan S, Chiodin G, D’Avola A, et al. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. Clin Cancer Res. 2019;25(8):2503–2512.
73.Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID–19-infected patients. Blood. 2020;135(21):1912–1915.
74.Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101.
75.Huwiler A, Pfeilschifter J. Sphingolipid signaling in renal fibrosis. Matrix Biol. 2018;68–69:230–247.
76.Barzegar M, Mirmosayyeb O, Nehzat N, et al. COVID–19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm. 2020;7(4).
77.Giblin PA, Lemieux RM. LFA–1 as a key regulator of immune function: approaches toward the development of LFA–1-based therapeutics. Curr Pharm Des. 2006;12(22):2771–2795.
78.Verma NK, Kelleher D. Not Just an Adhesion Molecule: LFA–1 Contact Tunes the T Lymphocyte Program. J Immunol. 2017;199(4):1213–1221.
79.Hussein HA, Walker LR, Abdel-Raouf UM, Desouky SA, Montasser AK, Akula SM. Beyond RGD: virus interactions with integrins. Arch Virol. 2015;160(11):2669–2681.
80.Borriello G, Ianniello A. COVID–19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. Mult Scler Relat Disord. 2020;41:102165.
81.Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol. 2010;63(5):311–317.
82.Saraste M, Penttila TL, Airas L. Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e292.
83.Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M. Dupilumab and COVID–19: What should we expect? Dermatol Ther. 2020:e13502.
84.Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH. Dual roles of IL–4 in lung injury and fibrosis. J Immunol. 2003;170(4):2083–2092.
85.Wynn TA, Cheever AW, Jankovic D, et al. An IL–12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature. 1995;376(6541):594–596.
86.Keane MP, Belperio JA, Burdick MD, Strieter RM. IL–12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2001;281(1):L92–97.